Differential regulation of cardiomyocyte survival and hypertrophy by MDM2, an E3 ubiquitin ligase - PubMed (original) (raw)
. 2006 Feb 10;281(6):3679-89.
doi: 10.1074/jbc.M509630200. Epub 2005 Dec 8.
Affiliations
- PMID: 16339144
- DOI: 10.1074/jbc.M509630200
Free article
Differential regulation of cardiomyocyte survival and hypertrophy by MDM2, an E3 ubiquitin ligase
Ambrus Toth et al. J Biol Chem. 2006.
Free article
Abstract
MDM2 is an E3 ubiquitin ligase that regulates the proteasomal degradation and activity of proteins involved in cell growth and apoptosis, including the tumor suppressors p53 and retinoblastoma and the transcription factor E2F1. Although the effect of several MDM2 targets on cardiomyocyte survival and hypertrophy has already been investigated, the role of MDM2 in these processes has not yet been established. We have, therefore, analyzed the effect of overexpression as well as inhibition of MDM2 on cardiac ischemia/reperfusion injury and hypertrophy. Here we show that isolated cardiac myocytes overexpressing MDM2 acquired resistance to hypoxia/reoxygenation-induced cell death. Conversely, inactivation of MDM2 by a peptide inhibitor resulted in elevated p53 levels and promoted hypoxia/reoxygenation-induced apoptosis. Consistent with this, decreased expression of MDM2 in a genetic mouse model was accompanied by reduced functional recovery of the left ventricles determined with the Langendorff ex vivo model of ischemia/reperfusion. In contrast to cell survival, cell hypertrophy induced by the alpha-agonists phenylephrine or endothelin-1 was inhibited by MDM2 overexpression. Collectively, our studies indicate that MDM2 promotes survival and attenuates hypertrophy of cardiac myocytes. This differential regulation of cell growth and cell survival is unique, because most other survival factors are prohypertrophic. MDM2, therefore, might be a potential therapeutic target to down-regulate both cell death and pathologic hypertrophy during remodeling upon cardiac infarction. In addition, our data also suggest that cancer treatments with MDM2 inhibitors to reactivate p53 may have adverse cardiac side effects by promoting cardiomyocyte death.
Similar articles
- Cardiac-specific ablation of the E3 ubiquitin ligase Mdm2 leads to oxidative stress, broad mitochondrial deficiency and early death.
Hauck L, Stanley-Hasnain S, Fung A, Grothe D, Rao V, Mak TW, Billia F. Hauck L, et al. PLoS One. 2017 Dec 21;12(12):e0189861. doi: 10.1371/journal.pone.0189861. eCollection 2017. PLoS One. 2017. PMID: 29267372 Free PMC article. - Ubiquitination and degradation of the anti-apoptotic protein ARC by MDM2.
Foo RS, Chan LK, Kitsis RN, Bennett MR. Foo RS, et al. J Biol Chem. 2007 Feb 23;282(8):5529-35. doi: 10.1074/jbc.M609046200. Epub 2006 Dec 2. J Biol Chem. 2007. PMID: 17142834 - LncRNA UCA1 protects cardiomyocytes against hypoxia/reoxygenation induced apoptosis through inhibiting miR-143/MDM2/p53 axis.
Wang QS, Zhou J, Li X. Wang QS, et al. Genomics. 2020 Jan;112(1):574-580. doi: 10.1016/j.ygeno.2019.04.009. Epub 2019 Apr 15. Genomics. 2020. PMID: 30998966 - Escape, or Vanish: Control the Fate of p53 through MDM2-Mediated Ubiquitination.
Wei J, Yang Y, Lu M, Xu L, Liu F, Yuan Z, Bao Q, Jiang Z, Xu X, Guo X, Zhang X, You Q, Sun H. Wei J, et al. Anticancer Agents Med Chem. 2015;16(2):174-89. doi: 10.2174/1871520615666150907093358. Anticancer Agents Med Chem. 2015. PMID: 26343143 Review. - A new twist in the feedback loop: stress-activated MDM2 destabilization is required for p53 activation.
Stommel JM, Wahl GM. Stommel JM, et al. Cell Cycle. 2005 Mar;4(3):411-7. doi: 10.4161/cc.4.3.1522. Epub 2005 Mar 2. Cell Cycle. 2005. PMID: 15684615 Review.
Cited by
- Xinnaotongluo liquid protects H9c2 cells from H/R-induced damage by regulating MDM2/STEAP3.
Cui J, Wang Q, Li M. Cui J, et al. PLoS One. 2024 Apr 19;19(4):e0302407. doi: 10.1371/journal.pone.0302407. eCollection 2024. PLoS One. 2024. PMID: 38640125 Free PMC article. - Protein homeostasis in the aged and diseased heart.
Mainali N, Ayyadevara S, Ganne A, Shmookler Reis RJ, Mehta JL. Mainali N, et al. J Cardiovasc Aging. 2023;3(2):16. doi: 10.20517/jca.2023.4. Epub 2023 Mar 7. J Cardiovasc Aging. 2023. PMID: 37092014 Free PMC article. - p90RSK Regulates p53 Pathway by MDM2 Phosphorylation in Thyroid Tumors.
Maietta I, Del Peschio F, Buonocore P, Viscusi E, Laudati S, Iannaci G, Minopoli M, Motti ML, De Falco V. Maietta I, et al. Cancers (Basel). 2022 Dec 25;15(1):121. doi: 10.3390/cancers15010121. Cancers (Basel). 2022. PMID: 36612117 Free PMC article. - Preconditioning-Activated AKT Controls Neuronal Tolerance to Ischemia through the MDM2-p53 Pathway.
Barrio E, Vecino R, Sánchez-Morán I, Rodríguez C, Suárez-Pindado A, Bolaños JP, Almeida A, Delgado-Esteban M. Barrio E, et al. Int J Mol Sci. 2021 Jul 6;22(14):7275. doi: 10.3390/ijms22147275. Int J Mol Sci. 2021. PMID: 34298892 Free PMC article. - The Role of HECT-Type E3 Ligase in the Development of Cardiac Disease.
Goto J, Otaki Y, Watanabe T, Watanabe M. Goto J, et al. Int J Mol Sci. 2021 Jun 4;22(11):6065. doi: 10.3390/ijms22116065. Int J Mol Sci. 2021. PMID: 34199773 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous